---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-020177"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T14:48:31.109320+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics expands at-the-market equity facility by $50M to $62M total

## Summary
- Amended Sales Agreement with SVB Securities to increase max aggregate offering from $12M to $62M, adding $50M in capacity.
- Shares sold in ATM offerings under Rule 415; SVB receives 3.0% commission on gross proceeds.
- Company will file a prospectus supplement under existing shelf registration statement (File No. 333-239499).
- No obligation to sell; either party may suspend the offering at any time.
- SVB affiliate Silicon Valley Bank is lender under a separate $14M term loan.

## SEC filing metadata
- accession: 0001564590-22-020177
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000156459022020177/0001564590-22-020177-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000156459022020177/trvi-8k_20220513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-020177
- JSON: https://secwatch.observer/filing/0001564590-22-020177.json
- Plain text: https://secwatch.observer/filing/0001564590-22-020177.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.